No FDAer For Commissioner, Interim or Otherwise, Rep. Stupak Urges Obama
This article was originally published in The Pink Sheet Daily
Executive Summary
Advice from the chairman of Commerce Committee's oversight panel dovetails in an odd way with what drug firms are telling the transition team - pick a nominee soon.
You may also be interested in...
FDA Succession Planning Targeted In Congress As Hamburg Heads For Exit
Margaret Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in the House 21st Century Cures discussion draft would mandate a similar process always be followed.
FDA Succession Planning Targeted In House Legislation
Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in 21st Century Cures bill would mandate a similar process always be followed.
FDA’s Von Eschenbach Returns To Texas In January; Will He Also Return To MD Anderson?
Von Eschenbach’s resignation is effective Jan. 20; FDA commissioner expresses hope that senior team will remain at least partly intact.